Flotek Industries, Inc. (FTK) Earnings Call Transcript & Summary

May 11, 2021

New York Stock Exchange US Materials Chemicals earnings 64 min

Earnings Call Speaker Segments

Danielle Allen

executive
#1

Thanks, and good morning to all of you. Here with me today and taking part in this call are John Gibson, our Chairman, CEO and President; Michael Borton, our Chief Financial Officer; TengBeng Koid, President of Global Business; and Ryan Ezell, President of Chemistry Technologies. During this call, we'll begin with prepared comments about our business and the results for the quarter. After that, we'll take whatever questions you might have. Our earnings announcement for the first quarter 2021 came out yesterday and can be found on our website. A webcast of today's call is happening now, and a replay will be posted on our website as well. Keep in mind that anything we say today about projections or what we expect for future events counts as forward-looking statements. Such statements carry a number of risks and uncertainties, and many of those are outside our control. Actual results could differ materially from what we currently expect because of these risks and uncertainties. Listeners should review our earnings release along with the risk factors covered in our filings with the SEC. In addition, please look at the reconciliations included in our earnings press release, since management might talk about non-GAAP metrics on this call; at this point I'll hand things over to John.

John Gibson

executive
#2

Okay, thanks Danielle, and good morning to all of you. We feel good about the strides being made in our operations, even with the hurdles we faced over the last 12 months. Sales and earnings for Q1 came in a bit under what we had projected, which stemmed from a sluggish beginning to the year, and then a significant upheaval in February caused by Winter Storm Uri that hit the whole supply chain. After that, in March, we were glad to observe demand rising considerably in both segments. Our team members continue to feel positive about what lies ahead for Flotek, and the company has grown stronger and more focused on delivering results as we pursue profitable expansion. With the energy sector placing greater emphasis on environmental, social and governance performance—ESG—alongside shifting regulatory landscapes aimed at cutting greenhouse gas emissions in half by 2030, we are applying our enthusiasm and expertise in chemistry and data solutions to lessen the environmental footprint of hydrocarbon production on our air, water, land and people. During the previous quarter, I personally held meetings with CEOs and C-suite executives at E&P companies to grasp their ESG approach and talk about how our chemistry and data offerings can assist them in reaching their ESG targets. What those discussions taught me is that the energy industry holds substantial EFC aspirations, and the most driven companies have ESG integrated at the C-Suite level and within their operations and supply chain choices. On top of that, at this point green chemistry isn't yet broadly regarded as a strategic tool in the ESG toolkit, but as operators refine their methods to bring down the total cost of ownership throughout the entire lifecycle of their programs, chemistry will grow into an important—even more important than before—factor; this is exactly where we work together to deliver value and lower liability. Flotek has long been recognized for a distinctive green chemistry that the EPA describes as cutting the use of hazardous substances, employing less toxic biodegradable chemistries, limiting spills and pollution, implementing real-time measurements and generating operational efficiencies. Given the massive quantities of chemicals that need to be moved, managed and pumped at the well site, the green effect—both monetary and ecological—is substantial. Looking at it from a digital transportation angle, our real-time monitoring and data solutions assess the makeup of crude with brand products every 15 seconds while it flows, with no need for a physical sample, which removes the danger of future diff missions. It additionally allows for automation of large-scale processes, aids in waste reduction and enhances reprocessing or removes the inefficiencies and reprocessing. At present our clients are employing this technology to shrink their carbon footprint, cut energy usage and lower emissions, and going forward our clients will have the ability to use our varied system to gauge greenhouse gases in real time within the pipe. We provide greener solutions throughout our enterprise, and that's the reason we are collaborating with leading in-base to suggest opportunities for lowering the total financial and environmental cost of ownership via our green chemistry and real-time monitoring. The discussions we've been having give me a lot of optimism, and there's plenty of opportunity for us to work together on making our industries more sustainable. Turning to how we did in the first quarter. There's pending litigation I want to talk about, and it concerns the terpene supply agreement we have with Florida Chemical Company. On March 29, through an 8-K, we let everyone know that the terpene supply agreement with Florida Chemical had been terminated, and the reason was that they wouldn't let Flotek exercise the contractual rights we hold to audit their books and records — something quite standard in a contract within our industry and throughout the supply chain. A lawsuit has been filed by us to recover money already paid out, specifically the $50 million payment made to ADM last year, and we also filed suit against ADM, after which they brought a counter action in Delaware. We're unable to talk about active litigation or guess at what the outcome might be, but our confidence in our position is very strong. Even with the supply agreement terminated, we hold enough terpene inventory, along with ultimate terpene supply sources, to cover what we need for the foreseeable future. On top of that, we don't anticipate that ending the supply agreement, or the litigation tied to it, will materially affect our operations or our capacity to serve customer needs. Going forward, the way we manage our supply chain will match terpene purchases to our demand. Because of that, selling excess terpene at a loss will no longer be necessary. Our top line might take a marginal hit in the near term from this strategy, yet the effect on our cash use and margins will be strongly positive. Now let me go over a few first quarter highlights. Our adjusted EBITDA got better on a sequential basis, mainly powered by strength in data analytics. Looking ahead, the growth opportunities within our Data Analytics segment have us excited, and it makes me happy that the first quarter stood as the best performing period for JP3 since we acquired it in May of last year. Top line is getting better and losses are getting smaller. Progress continues on entering international markets, and TengBeng will cover more on that in his comments coming up, including how things are going there and his enthusiasm for the business. Let's move to chemistry technologies. If you set aside the terpene purchases that showed up in earlier quarters, our Chemistry Technology segment got better from quarter to quarter, with domestic improvement during the first quarter coming strongly from energy chemistry. I'm also happy to share that 2 talented leaders have joined our Chemistry Technology segment: Nathan Snoke, coming aboard as Vice President of Energy Chemistry, and Matthew Sullivan, coming aboard as Vice President of Professional Chemistry. Ryan will tell you more about what they've done and where they come from, but I'm certain both will be key to bringing our Chemistry Technology business up to the next level. Also — on the personnel side, I feel encouraged by how many people are now looking for work with Flotek. It's wonderful to see folks reaching out and wanting to be part of the team. Now, let's shift our focus to expenses and our liquidity position. Safeguarding the balance sheet stands as one of our top priorities, and right now we're actively reviewing a wide range of moves — things like selling real estate that isn't core to us, sale leaseback transition — transactions, and looking at an asset-based launch, alongside other possibilities, so we can boost our financial flexibility and supply the working capital that we believe will be necessary as the market keeps recovering and we expand. To every one of our shareholders, I want to give my assurance: we are committed to strengthening financial flexibility, and our intention is to accomplish that without diluting value for shareholders. One more thing deserves mention as well — because of Winter Storm Uri, which we discussed on last quarter's call, we felt the effects of those broad, historic force majeure declarations throughout the whole petrochemical supply chain. Consequently, we've witnessed a rising price environment, together with constrained availability of some raw materials. Our approach remains to draw on our supply chain relationships and keep cost under control amid this inflationary environment. For more specifics about the quarter, I'll hand things to TengBeng, who will talk further about our Data Analytics segment, then to Ryan for an update on our Chemistry Technology segment, and finally Mike, who will walk through our financial results in greater depth. TengBeng, I know you're excited, so over to you.

Teng Beng Koid

executive
#3

Thanks, John. Yes, that's right. During Q1, we stayed highly focused on carrying out our strategy and made meaningful headway on every front; we're glad to observe ongoing gains in financial results within our Data Analytics segment. Over the last 2 quarters, revenues saw sequential growth in the double digits. Operating margin also came up considerably; during the quarter just ended, we brought in a number of new clients and saw repeat purchases from those already with us, among them a super major oil company. In fact, 1 major midstream company that started as a customer in Q4 returned and bought multiple systems in the last quarter. These repeat instances demonstrate the value delivered to our customers by applying our game-changing technology. We advanced on the global side as well. Our direct analysis for markets abroad is undergoing an extremely thorough certification process. Although this process requires time since it entails multiple certifications, we're progressing well and the project is on track per plan. At the same time, we moved forward with international business development work. In Q1, we finished a site survey — our first pilot overseas — with a leading oil and gas company in the Middle East. We're also in the middle of arranging a further site survey for a second pilot, likewise in the Middle East. These key milestones give us encouragement, even with the difficulties caused by being unable to travel and meet these customers throughout the pandemic. When it comes to technology development, we keep putting substantial resources and effort in. We launched our initial application that uses machine-learning algorithms, focused on batch interface detections for pipelines. This new application, named advance interface detection algorithms, or AIDA for short, was installed successfully at 2 locations. AIDA lets customers make batch cost decisions more quickly, which cuts down batch interfaces and boosts profitability; this new application requires no sample, meaning no samplers; we're also examining a number of mid to long-term technology development projects. Regarding ESG, as John noted, our technology offerings have assisted companies in lowering their carbon footprint, cutting energy consumption and reducing emissions. For instance, many of our systems are deployed in condensate and crude stabilizers. The technology we use in this stabilization unit delivers real-time data that assists customers in producing more liquid and less gas, while still meeting the specifications needed for storage and transportation. That cuts both emissions and energy consumption. JP3 is having an effect on bettering the environment, helping customers enhance their ESG performance. To sum up, we've achieved meaningful headway in executing our strategy across every front. Our game-changing technology, supplying real-time data and analytics, helps customers transform their businesses. Our customers gain from the exceptional value we bring. Our future is extremely bright; with that, I'll hand the call over to Ryan, who will talk about our Chemistry Technology segment.

Ryan Ezell

executive
#4

I appreciate that, Koid. I'll start by covering how our Chemistry Technology segment performed. To begin, I want to walk through the highlights in our energy chemistry technologies, and after that I'll offer some commentary regarding our professional chemistries, which encompasses the Flotek Protekol brand we recently brought to market — a line of cleaning, disinfecting and sanitizing products registered with both the EPA and the FDA. Back in the fourth quarter of 2020, we brought Flotek back into the markets so that our aim of becoming the chemistry partner of choice would be more visible — the partner that delivers ESG-focused operational cost efficiencies while boosting well production for our customers. Embedding our ESG initiatives forms part of the value proposition we offer: cost-effective, environmentally friendly, safer chemistry solutions that assist operators in raising production while lowering cost per barrel. Beyond that, we sharpened our sales strategy to match a variety of domestic and international customers, covering E&P operators along with oilfield service companies. So far, the market has responded well to what we offer, and the pace at which interest is converting into executed sales pleases us. Turning to the domestic side, revenue improved 56% sequentially from one quarter to the next, since we broadened our customer concentration across E&P operators and oilfield service companies; and even with the winter storm's impact, we managed to mobilize and carry out key field trial applications of our green reservoir centric technologies with major independent operators. We remain optimistic that targeting customers who have sustainable activity and operational programs — especially those in unconventional shale markets — will keep paying off, as our value proposition of cost effective chemistry solutions that enhance production while improving overall ESG impact earns positive reception. As for the national front, diversification and expansion stay a key area of focus for our Energy Chemistry business. We're positioned well to capitalize on substantial growth opportunities, notwithstanding modest headwinds in market conditions across the Middle East and Asia Pacific regions. March is bringing us momentum, with quarter-to-date results surpassing Q1, through deploying custom chemistry solutions to major NRC's and service companies throughout the Middle East, Africa and Europe. Then, last year, we seized the lull in activity to concentrate internally on transforming our Chemistry Technology segment. We trimmed operational costs and sped up efficiencies within our business processes, and we set defined metrics for measuring continuous improvement. As we move ahead into 2021, our attention has turned to executing on our transformed business, and upon finishing the first quarter, we're seeing solid operational gains stemming from a leaner business; we managed to cut inventory while growing revenue, we lowered costs throughout operations with further decreases in freight charges and equipment rentals measured as a percentage of revenue, and we keep right-sizing our footprint for in-basin delivery through better strategic sourcing, which let us close an underutilized facility that wasn't core to our service delivery or value proposition. Carrying out these programs has let us make our operations even leaner, aiming to push us toward positive EBITDA and cash flow. Then, it's my pleasure to introduce Nathan Snoke, who joins the team as Vice President of Energy Chemistry. Nathan brings deep experience as a worldwide leader in specialized oilfield services, having held positions across more than 2 decades that stretch from field operations to top-tier management on several continents. He comes to us from Halliburton, where most recently he served as Senior Region Manager for Europe, Eurasia and Sub-Sahara Africa, working out of London. We're thrilled to have him aboard and eager to see him help carry out our growth strategy. Turning now to professional chemistries. In Q1, volumes rose overall on a sequential basis while revenue dipped a bit, driven by pricing pressure in a fiercely competitive market. Even though January got off to a slow start because of the holiday season returning, we're happy with how sales momentum kept building through the quarter, with March standing out and that strength carrying on to today, as Q2 revenues beat Q1; and yesterday, we shared news that Matt Sullivan is coming on as Vice President of Professional Chemistries, a 30-year veteran of the janitorial and sanitizing sector. Matt is a seasoned leader who joins us from Georgia-Pacific, where he took on various leadership posts, most recently as Director of Sales for the Northeast Market for GP Pro. Matt also held sales and marketing positions at Kimberly Clark, Scott Worldwide and Clorox Professional, and helped grow technical concepts, the global leader in restroom automation systems; we're excited that — for Matt to use his experience and relationships to fuel growth in this segment, as we keep building our business over the long haul; and throughout the past year, we managed to increase production, our branding and marketing, and established a dedicated sales team with market know-how to capitalize on our specialty chemistry capabilities and broaden our corporate revenue stream. We're happy with the progress achieved on an accelerated time line and we're well positioned to sustain strong momentum and growth; and I'll hand things over to Mike Borton to go over our financial results.

Mike Borton

executive
#5

Thanks, Ryan. To build on what John said earlier, Q1 came in a bit under what we had projected, and we got off to a tough start as COVID-related demand issues and maintenance interruptions from Winter Storm Uri hit us. That said, we're encouraged that March showed strong momentum, which has carried over into the current quarter. Consolidated revenue for Q1 totaled $11.8 million, a 2.8% drop from $12.1 million in Q4, and under the $19.4 million recorded in the same period a year ago. Looking at segments, Chemistry Technology revenue fell 5% quarter over quarter to $10.3 million. Two things drove that decrease. The first was the ending of our supply growth ADM arrangement and the related move away from selling raw inventory terpene during the quarter. Once you strip out terpene sales, the segment actually improved, rising 7.1% on a sequential basis. Taking a closer look at energy chemistries, our domestic energy business showed tremendous strength, up 56% sequentially even with February's winter storms, and we finished the quarter strongly. International sales also contributed to that growth, though they were affected by broader declines in market activity, weather, and supply limitations during the quarter. The way it sells to future quarters — finally, chemistries as those start to the year to build momentum in the second quarter. For Data Analytics, sales rose 16.7% sequentially, mainly on higher new product sales in North America; that marks the second straight quarter of sales growth and the best quarter since the JP3 acquisition. Consolidated operating expenses came to $13.8 million in Q1 2021, down 43.4% from the prior quarter and 89.6% lower than last year's $22.8 million in Q1. The Q1 2020 declines resulted from cost reductions tied to lower revenue, plus reduced operating expenses from many steps taken to cut the company's costs. Corporate G&A dropped 2.9% to $4.4 million from $4.5 million in last year's first quarter, thanks to personnel costs and severance incurred in Q1 of last year and lower occupancy costs after the company left its corporate headquarters and consolidated into its Global Research and Innovation Center. Corporate G&A rose from Q4 2020 by nearly 7,000 due to higher one-time legal fees and all of these tied to 10-K from higher seasonal tax rates, partly offset by lower compensation expenses. Research and development costs were $1.5 million in Q1, roughly flat versus Q4 and $1 million below last year. We posted a loss from operations of $8.3 million, or $0.12 per diluted share, in Q4 of 2021. That's a major improvement from last year's loss of $64 million, or $1.07 per diluted share. For Q1, adjusted EBITDA came in at a loss of $6.6 million. Even with onetime legal costs and increased audit fees folded in, that figure beat the prior quarter's loss of $6.8 million and came in a touch better than the $6.3 million loss posted a year earlier, which was achieved on revenue that was $7.7 million lower. In running this business, we stay absolutely committed to squeezing out cost efficiencies, expanding the top line while the market keeps healing, and producing cash that we want to put toward growth. Now on to how the balance sheet performed. Keeping our liquidity intact stays a priority for us. When Q1 wrapped up, cash inflows stood at $33.9 million, compared with $39.3 million during Q4. Thanks to the disciplined way we operate, our cash fell quite steeply in Q1 relative to the previous 3 periods. Operating losses along with earlier severance agreements weighed on our cash position, though better working capital offset part of that; altogether, we carry $5.7 million in loans still due under the Paycheck Protection Program tied to the CARES Act. So in a technical sense, we'll be tracking those loan figures over the coming several weeks, and also tracking the employee retention credit. On top of that, we're converting non-core assets into cash, among them our Monahans facility, which right now is listed for sale. Beyond that, talks with a range of funding sources regarding our asset baseline have been quite constructive. On our balance sheet during Q1, there was a crude liability of $9.4 million recorded in Q4 tied to the company's anticipated use of terpene and the supply agreement with ADM. Although litigation was brought against ADM only days prior to Q1 ending, no changes were applied to balance sheet liabilities across that quarter. Still, going forward, we'll keep reviewing and assessing that $9.4 million balance in light of accounting guidance. Having said that, let me restate that we have no plans to purchase terpene for a minimum of a year. Before I wrap up, I'd like to extend a welcome to <<inaudible>>, who will oversee our enhanced internal control process and handle remediation of biomaterial weaknesses; having a leader with this much experience join us is thrilling, and we're eager to pursue a driving program for this. With that, I'll hand the call back to John for his closing comments.

John Gibson

executive
#6

Okay, thanks, Mike. So as you've been hearing, we've got momentum now, and we're feeling good about what's ahead for every one of our business lines in the back half of this year and going into 2022. Let me give you a quick rundown of some key points; our suite of green chemistry and data analytics solutions really matters to this industry. The environmental advantages of our products are what our long track record and sustainable chemistries were founded on, and now we've given those green advantages a lot more power by assisting in generating operational efficiencies that cut pollution, cut waste, cut emissions, and cut the total cost of ownership. The way we work with our customers is speeding up market chances for us, and we're eager to join forces to boost ESG performance industry-wide as we all pursue a shift toward a planet with cleaner energy, cleaner water, and cleaner air. Dr. Silas and our research and innovation team have been at the heart of our environmental record, and with our strong strategy, they'll keep pushing this company ahead. Making the effect of the chemistry lifecycle on our customers' objectives — especially their ESG objectives — clear is our mission, and in the months ahead we intend to launch a new website that better reflects how the company is turning green now. We're happy to report solid advancement in our data analytic segment along with ongoing sequential growth and shrinking losses, combined with international chances that lie ahead. Regarding JP3's growth, we're truly enthusiastic. Energy chemistries still drive a large portion of our Chemistry Technology segment, and we're delighted by the 56% sequential revenue gain in the domestic market, plus the upcoming prospects we foresee in the Middle East. On the professional chemistries side, we've brought in someone with great potential and decades of experience: Matt Sullivan. Our goal is to turn into a meaningful long-term supplier for the JanSan market, which is a market expected to see a near double-digit CAGR over the coming year. Last, we stay responsible stewards of our balance sheet; we're pursuing continuous cost cuts, turning non-core assets into cash, and assessing sensible lines of credit, so we'll have the working capital we view as essential for growth both domestically and internationally. With that said, I thank you for joining the call. We'll now take questions. Daniel?

Daniel Burke

analyst
#7

John, it's good to learn that things got busier as you wrapped up the first quarter. Would you be open to sharing some sense of how revenue might shape up in Q2, perhaps even just working off the April pace?

John Gibson

executive
#8

I believe I can put it this way without risk: my expectation is that Q2 comes in ahead of Q1. The exact size of the improvement depends on finalizing deals and moving ahead, yet nothing on our plate at the moment appears unlikely to deliver a step up from one quarter to the next.

Daniel Burke

analyst
#9

So the whole effect — and I understand it, it was — it helped the bottom line, but the entire effect of stopping the resale of terpene, won't that create a sequential headwind of scale?

John Gibson

executive
#10

Well, that's the problem with selling a product where you take a loss each time you sell it. And so we had a take or pay contract in which we were purchasing far more than was needed and then the sole method to recover the cash was to sell it at market. And so we were selling it as fast as possible to preserve our cash, so we wouldn't simply be left with inventory that turned into excess or obsolete; so the entirety of the cancellation of that up, I was somewhat surprised that they would breach, but we won't say much about that mix here, but it did provide a chance to cash let contract which there's no doubt was in the company's best interest. And then we — because we couldn't audit it made us wonder whether we ought to go back and attempt to recover amounts already paid and that's what the lawsuit is for.

Daniel Burke

analyst
#11

And so, I suppose my next question would be about the professional chemistry segment. It's encouraging to watch you folks keep expanding the team in that area, since you're able to make quite a few distinct items at this stage, along with plenty of varied packaging. I realize this was definitely covered in the opening remarks on this call, but I'm curious whether you might once more point out a few of the chances you're seeing right now in professional chemistry, plus some items or categories of emphasis that will matter most across the coming 6 months, 12 months?

John Gibson

executive
#12

That's a wonderful question, and Matt Sullivan happens to be seated in this room alongside us, and I won't place him in an awkward position during his first days in the role, yet we truly possess an excellent lineup of items. We operate within a market that has an anticipated CAGR near double digits, and it isn't wholly tied to COVID — those sorts of CAGRs were around prior to COVID and simply keep moving ahead as folks place heavy importance on health, cleanliness, and disinfecting; therefore our product lines — I value how you framed that question, since we aren't a sanitizer company. We hold a full range of offerings, which covers the degreasers, disinfectant, wipes. And I think Matt — what we'll do during our upcoming call is bring him on to explain how the market is evolving and where we identify chances, though it will probably concern portfolios of items. Individuals usually purchase single items, yet they seek that portfolio, and we currently provide a highly strong selection that we can describe. And I believe Ryan may have mentioned this, but April, May, I mean we have — you'd like to say something, correct?

Ryan Ezell

executive
#13

Yeah, I suppose our run rates keep getting better. We sort of went through that crossover point where, with pricing pressure, volume was expanding while revenue was somewhat declining. At this point, though, both revenue and volume are growing, and what's unique here is that, thanks to the portfolio's diversification, as John pointed out, we aren't leveraged only in sanitizers — our cleaners, degreaser, and that cleaner line are truly rooted in a great deal of core chemistry we do involving our surfactant and our use of green biodegradable chemicals with the terpene. Those have — they hold a solid position in the market that we're beginning to watch evolve and develop nicely. And I believe that with mass experience in our channels to market plus the portfolio diversification, it will only assist us in speeding up this growth even more.

John Gibson

executive
#14

I remain quite hopeful regarding this, Daniel, and there's a second intriguing factor behind that. Thinking about COVID, its actual effect was to complicate every kind of testing, since early on people built up stockpiles, which meant you never saw those items return to the market as purchases. That produced unevenness and made forecasting hard. What's wonderful about our present situation is that we possess an excellent array of products, plus the talent right here to genuinely go after and connect with the customers who purchase that — that collection of products — and the markets are settling back, as folks work through the inventories they acquired 2 months ago along with March of last year; and my view is that we'll witness growth in that market returning to normal, and it will add a great deal of value to our chemistry business as a whole.

Daniel Burke

analyst
#15

Alright, perhaps I'll pose a final item, and it concerns JP3. If my ears caught it properly, you attributed — among the factors behind revenue rising sequentially was, as I understand it, product sales within the U.S. And I suppose what I'm after is an update on how things are progressing with the shift toward a greater service model?

John Gibson

executive
#16

Please continue.

Teng Beng Koid

executive
#17

Appreciate that, Daniel. The shift is still underway for us. Clearly, what we're aiming at going forward is boosting ARR along with every bit of recurring revenue, so that's the direction we're pushing in at this moment.

John Gibson

executive
#18

Daniel, this is a fascinating business as well, in my view. A number of parties have reached out to us — probably big consulting firms and service providers — wanting to build out workflows that leverage what we offer in measurement and analytics. So I'm starting to see that — and this may be a bit of a stretch, so please don't criticize me for exaggeration — if you looked back 20 years to when SAP launched, the actual money came from the Deloitte's and Accenture's and the KPMG's, the folks who implemented SAP. And to truly speed up growth in this area, Koid and I have a number of meetings lined up related to securing those high level workflows and getting companies to fully exploit this system, this measurement system; and my sense is that will also assist us in generating more annually recurring revenue, assuming we can get those workflows deployed, and I'm quite enthusiastic about the discussions taking place there.

John Bair

analyst
#19

I have a few things I'd like to ask. Beyond the conventional oil and gas E&P sectors, which additional markets or industries might be a good fit for your green specialty chemical products?

John Gibson

executive
#20

What's interesting is that if we're able to gain that traction, staying sharply focused could bring us back to profitability. Our chemistry has plenty of possible uses beyond oil and gas. I can think of — I have, I'll leave it at that, I have — agricultural possibilities have come up before. What I mean is achieving the effectiveness of herbicides, pesticides, and insecticides comes from being able to spread those chemicals evenly across leaves and stems, and we possess the scientific know-how to accomplish that. We've actually had a few discussions about developing coatings for various types of glass that could serve other industries, and we have the chemical expertise for that; however, I believe our true advantage right now lies in that green dimension, and in the fact that we rely on biodegradable chemicals, which would likewise break down naturally in agriculture. The possibilities are numerous. I won't limit us to any one area, but I will keep us limited to maintaining focus until we reach profitability, instead of chasing every opportunity and spending money when you know that entering those markets would require a year or more of development. And at this moment, I don't believe that would be the wisest course of action for us.

John Bair

analyst
#21

Could you also give us a sense — you mentioned part of this earlier — of how you're handling outreach to both E&P operators and oilfield service providers? How do you strike that balance when dealing with the major players compared with the service companies and similar firms? Where does your attention sit? Which companies are you actually going after, and which ones do you believe will adopt what you're doing and what you're offering the fastest?

John Gibson

executive
#22

You sound like a Flotek board member with that question. That's a great one. Let's shift things around a little. To start, we've already put in a lot of effort on the recovery side, and we currently have strong discussions underway with oilfield service businesses, which at one time served as Flotek's largest channel before the company chose a direct route and halted its use of indirect channels. Well, we now have very productive talks happening with the service sector, and my expectation is that this momentum will build moving ahead. Next comes engaging customers, which is another excellent question. I've spoken with chief executives running businesses whose market caps stretch from roughly $0.5 billion up to $100 billion or beyond, and the differences show up here: the place we can make the fastest, biggest difference is among the smaller firms that lack enough personnel to properly conduct a green scorecard on their chemistry. What we can then do is examine their current chemistries closely and explain to them how — including in areas where our products aren't yet available — they ought to follow a route for shifting away from those toward greener chemistry, allowing them to strengthen their sustainability. Right now, nearly every CEO is willing to have that kind of discussion with you. Once you reach the bigger players, though, they've got sizable departments they can direct that question to, so handing that work off to a firm like ours becomes less probable — yet that middle tier exists, where genuinely productive discussions are taking place, we're making a huge difference there, and our traction has been fairly strong. So we're examining every part of this. One CEO — I won't say who — spent our whole conversation about ESG, when I raised it, on how intensely focused his company is on cutting waste. So the only thing he cared to talk about was how much waste you could remove from the picture. As you shift toward greater chemicals, there's less waste to begin with, since the biodegradable quality means recovery worries you less. Yet when you consider the complete picture of everything being used, one element Ryan contributes is that big-picture perspective on lowering the overall amount of chemicals consumed, cutting how toxic those chemicals are, boosting how readily they break down biologically, and shrinking the greenhouse gases tied to moving them between sites. That explains why you notice a shift toward drive far for us — the point being you avoid hauling enormous quantities of water out there, since on-site water can be used instead. The whole focus must be on the full scope of cutting CO2 and methane at the wellsite, and our chemistry-related offerings, we believe, will deliver substantial gains for our customers in that area — gains measurable enough to become part of their ESG initiatives moving ahead.

John Bair

analyst
#23

So let me pose this: it sounds like the majors — the larger companies — might come to Flotek just for product rather than a full bundle of services plus materials. Is that how I should read it, or am I off base?

John Gibson

executive
#24

No — that's actually the correct way to frame it. With the super majors and the NOCs, they'll be capable of evaluating their own chemistry ESG, yet every one of them wants those products as an outcome of that evaluation. For others, we're able to assist with the assessment as well as the products. So you've got two distinct sales motions: one where you satisfy their ESG requirement, and you generate that demand by getting them to see that chemistry belongs inside their ESG and sustainability efforts. When you reach out to folks today, I'd estimate 80% plus haven't genuinely incorporated chemistry into their ESG planning — they get fugitive emissions and valves. That's something you can check on — they're spending heavily on upgrading valves to get rid of methane emissions and fugitive emissions. They're also very active on water, since water production, water injection, induced seismicity, anything tied to water base — we must reduce the water we produce and inject, and where we inject it. So that matters a great deal. I believe they're simply — as they progress, they're extremely ambitious about this. We want hydrocarbons to be a clean-enough energy source that it remains sustainable over the long term; and as a result, we must be accountable for and build improved solutions for everyone I speak with — they'll keep evolving chemistry as the following phase. It appears that now, having somewhat dealt with water and dealt with the air, we also must deal with water by first targeting what could contaminate it, what could injure our employees when we apply it in the field — one we've mentioned previously, xylene, which isn't the proper chemical for field use, and we have chemistry able to substitute for it. And we're thrilled about removing xylene. We believe that's a major opportunity for us to pursue and sell hard, since we can remove the effect on employees, the effect on the environment, possible contamination of aquifers — every one of those can be removed by using a biodegradable product made from terpene.

John Bair

analyst
#25

When you compare them with tailings and the standard chemical blend, do those biodegradable options make financial sense?

John Gibson

executive
#26

A pair of developments occurred. First, we discovered that these products deliver strong efficacy even at reduced concentrations. So, to begin with, by relying on those lower concentrations, we cut the expense of employing them. Yet there's a second development, and I'll hand that one to Ryan: because of supply chain disruptions and similar factors, the market for the competing products — their prices have climbed. Would you agree with that, Ryan?

Ryan Ezell

executive
#27

Yeah, and what I'd add is this: if you're drawing a direct line to BTX, you're really putting a highly toxic environmental product up against something biodegradable. Then you've got those other mutual solids showing up, where you see part of the monobutyl ether alongside some of the rewards, because harm to certain plants from the storm continues, and supply chain disruption too. Believe it or not, our dab paintings and the biodegradable solvents we offer have actually shifted toward a solution that's more cost-effective right now. And once you weigh total cost of ownership against BTX — factoring in extra handling, the safety dimension, whichever way you frame it — it still comes out as a better TCO, total cost of ownership, across the whole service delivery model. So that's the key thing I think we're getting at with the collaboration we're pushing through these conversations: evaluating that entire value chain is what will make the difference, since it's sometimes tough to compare some old x per payout against this per payout. That isn't the real total cost of ownership, though, given the additional touches or the mediation methods that happen after use, or the cleaning of tanks, totes, and every other component, plus disposals. So for me it isn't just about impact — the total cost of ownership is significantly better with certain biodegradable solvents and how they're applied, whether that's remediation, reservoir centric treatment, or even displacements on the drilling side.

John Gibson

executive
#28

You know, it's kind of a constant exercise to figure out which route gets you money soonest and with the least friction. When the pitch involves boosting output or lifting recovery rates, that sale becomes far tougher and far more granular. You end up dissecting a whole web of variables — what the well's mechanical side does, what skin beverage does, what perforation design does at each stage and cluster. That's — a serious amount of effort is required. Then there are clients who've already walked that road, and with them our effect on their results is substantial; yet with most buyers, that 85%, if you can instead discuss cutting liability, ESG results, staying cost competitive, growing margins and hitting their sustainability targets, that conversation is way simpler than running a tactical evaluation of how you perform amid countless moving parts. How will you raise production? Among sophisticated clients, we do really well at this. For those feeling the sharpest pressure from efficiency and cost cuts, we've got a narrative now, so they aren't a market we've written off.

John Bair

analyst
#29

Just one final quick item — really a quick one — since either my connection wasn't too clear or that part about the PPP loan, which I did pick up, I believe you intend to seek forgiveness on it. Would you mind going over what you said about that once more.

Mike Borton

executive
#30

Sure. So what we have — the amount still outstanding — well, it's a PPP loan, and within the coming 2 weeks, we'll get together regarding the forgiveness that's permitted based on what we report. And I will be there during those 2 weeks.

John Bair

analyst
#31

So would that be a 100 — is this a partial forgiveness request, or is it a full one?

Mike Borton

executive
#32

We'll proceed depending on whatever we're permitted to do; we're probably not prepared to disclose that figure yet, but we'd like to aim toward the maximum allowable amount we can submit for. And we're going to seek the employee retentions credit as well, which will be a significant number for us in Q1 and Q2 of 2021 for those who are eligible; so we are also applying for the employee retention credit and we've actually all are starting to see the benefit of that in Q2.

John Bair

analyst
#33

And is it necessary for the Flotek PPP loan to be part of the main one? To put it another way, is it possible for you to put Flotek together with JP3, or must these be filed as 2 distinct applications?

Mike Borton

executive
#34

We're filing 2 distinct applications. The one for JP3 is being submitted separately from the Flotek one.

John Gibson

executive
#35

That's really a wonderful question. I'd suggest you reach out to us and follow up — we'd be glad to speak with you while the window is still open here. So I think at this point we'll move on to our next question.

Eric Swergold

analyst
#36

I have a couple of things to ask you today. Can you hear me clearly?

John Gibson

executive
#37

Absolutely.

Eric Swergold

analyst
#38

My first inquiry goes to TBK. At this point, how booked up is your schedule when it comes to securing meetings with buyers? You brought up that some headway is being made in the Middle East. At what point do you expect you'll truly be in a position to meet clients in person? Then, John, my second inquiry is directed at you. Could you refresh our memory regarding the compensation plan — I'm unable to recall if it was $7 or $8 per share, where, should that goal be reached across a set stretch of time, you fellows arrange to earn a bit of cash for yourselves? Much appreciated.

John Gibson

executive
#39

I'll take care of that. Koid?

Teng Beng Koid

executive
#40

Eric, when it comes to U.S. or Southern, you'll have the chance to meet with customers. As a matter of fact, a handful of customers are already letting us come into their offices—not a lot of them—so usually the get-together happens outdoors, over lunch or coffee and that kind of thing. If not, the meeting can take place via Teams or Zoom. On the international side, those meetings likewise all happen through Teams and Zoom, since traveling isn't permitted—not for those of us here, but even for our colleagues based in the Middle East, they can't meet customers in person, so travel is truly limited to joining Zoom calls and Teams calls. So there—clearly nothing is happening in person, but even so, I believe we've been managing to work through it in spite of the difficulties of not being able to meet in person. And I'd say it's progressing quite nicely, and we have plenty of discussions, repeat discussions with customers, the very same customers, and that shows you that—interest is quite strong on the international side throughout Asia and the Middle East too. And more recently, we've even been receiving inbound inquiries from Africa, for instance, West Africa. So those are developing quite nicely.

John Gibson

executive
#41

I'm going to apply a bit of pressure on TengBeng at this point. Every gain you're noticing with JP3 comes from sales here at home, since our internationalization efforts aren't complete yet, and we have a truly substantial pipeline abroad, India included. It would be fair to conclude that in India, those efforts stopped because of the COVID crisis happening there right now. So India remains in our thoughts and prayers. That said, enormous opportunity exists for us there, plus the Middle East and Africa, and so on, yet we've generated no revenue internationally at all. What Koid has accomplished is genuinely getting things back on track within the domestic market, and we're truly witnessing growth emerge there. We're putting in hard work on internationalizing that product, making excellent progress, and the business development pipeline along with the pilots all confirm we aren't burning any wall clock time on it. Once our international product is ready, we'll be in position to roll it out to sales right away. So I believe one question we must raise every time is: where do we stand on Verax's internationalization, and Koid is able to address that. The activity level internationally is extremely high; I know Koid has worked nights and early mornings. When you're communicating with the Middle East, that typically begins around either 8:00 or 9:00 p.m. and stretches late, so our team is very connected there. Regarding the question you raised about our compensation, as the old saying goes, from your lips to God's ears — $7 a share, I'd earn some money, Eric, and I would have hoped we could have reached that in a shorter period of time. But it appears COVID did sort of slow things down. We also needed to refocus the company to the point where we've now rebuilt the relationships with the indirect channel. We have a genuinely strong strategy for how to be — how to sell across the whole market, not merely people in enhanced oil recovery, or EUR; we can now boost their efficiency and their sustainability, their ESG goal. So I'm still here for $7, that's what I came for, and I'm focused on it. We do have hurdles that come up in the $3 range, in the $5 range, in the $7 range, and I intend to get over those hurdles within the next 12 months. So as we move forward, I'd like to say let's clear at least 1 of them before the year ends. And so we're focused on getting turned around and gaining access to working capital, which we need in order to truly seize the growth opportunities we see ahead of us.

Joseph Von Meister

analyst
#42

Alright, strong results, and I suppose we have some worry regarding the ongoing cash burn. I'm certain you share that concern. At what revenue figure, in dollars, would you reach EBITDA breakeven? And I've got two more questions to ask afterward.

John Gibson

executive
#43

Alright, I'm having a bit of difficulty here. Could you say that again for me, Daniel.

Joseph Von Meister

analyst
#44

I asked, how much revenue do we need to reach breakeven?

John Gibson

executive
#45

So, what amount of revenue gets us to breakeven.

John Gibson

executive
#46

Regarding the EBITDA line, that's a solid question, and honestly it's something we go back and forth on, since it hinges heavily on mix, and also on what we're forced to shell out for every product further down the supply chain, given that we've witnessed some inflation there in how much of that pricing we can push through and how that hits us. So it's obviously going to land somewhere past $100 million — that amount will be required — and we keep grinding away at our cost structure so that I'm able to bring that figure lower. So we'll keep pushing to get it down to whatever level is feasible, to smaller figures. So I'd kind of put it this way: once you begin approaching $100 million, you'll begin getting nearer to — closer to breakeven; we'll be within striking distance.

Joseph Von Meister

analyst
#47

Is reaching that point possible within this year, or can't we know yet? That strikes me as reasonable to ask, since you currently operate 3 offerings rather than 1. A single offering previously generated roughly $45 million to $50 million per quarter in revenue, and at present — honestly, I have no idea what it brings in, since you don't disclose it separately. So given that you have more than 1 engine to watch, more than 1 business segment to watch, the question isn't out of line.

John Gibson

executive
#48

Alright, that's an excellent question, since what you're requesting is a forward-looking statement, and, Joseph, I would feel let down by you if you weren't attempting to extract as much as possible from our major good, and I would feel let down by myself if I gave an answer. So let me try to see how close I can get. Back when I first came aboard, I did make a guess about breakeven, and that hurt me partly too, because once I said it, I committed to taking no form of remuneration until we reached break even. My wife has urged me not to make that pledge a second time. That's among the reasons we won't provide a forward-looking statement about when I will break even, and even then I still won't accept the bonus, since I picked up a valuable lesson: not everything is within my control. I believe you must factor in normalcy, COVID, and the market's recovery, demand's recovery, yet what excites me are the things beyond our control. I believe we have a solid hold on our expenses and we'll keep concentrating on that; we grasp well which assets are non-core and which ones we will sell off to finance our working capital requirements and or to have the best impact in the near term; and so as soon as possible is when breakeven happens, that would be the correct response. I'm requesting that people achieve it this year, and I would be delighted to have it finished this year, but as for when I'll forecast it — I would say, I'm going to pass. I'll attempt to respond to that.

Joseph Von Meister

analyst
#49

Regarding PPP, are you anticipating full recovery of that loan?

John Gibson

executive
#50

At this point, I'll respond. Our goal is to — formulas exist on our end that establish what can be recovered, and we intend to request the highest amount available to us. Whether public or private companies get different treatment remains to be determined, but we'll apply for the maximum. I feel quite sure we'll have a meaningful share of it forgiven — that's what we're aiming for — and for those listening, we'll share the details once we have some sense of the figure. It's roughly in that order. I regret not having taken on some borrowings, because then we could show everyone how we stand relative to our covenants at present; in fact, we still hold quite a bit of cash. Looking at our quarterly figures, our Q1 cash usage came in lower than in earlier periods, and we aim to spend less cash in the coming quarter than this one, and even less the quarter following. So my sense is we're moving toward breakeven now, and we have solid product strategies backing that up, which is likely the strongest position we've occupied in about 12 months.

Joseph Von Meister

analyst
#51

John, I've got 2 additional questions, and here's the first one: what did international revenue look like this quarter, if there was any?

John Gibson

executive
#52

Are you referring to Q2 or Q1? Okay, let me just give you a general picture.

Joseph Von Meister

analyst
#53

That's the one you just mentioned.

John Gibson

executive
#54

All right. Mike, what about international revenue for Q1?

Mike Borton

executive
#55

Yeah, obviously it's lower, correct, since we observed the chemistry segment increased — actually, the domestic portion rose 56% — so obviously the international side fell, right, it dropped to navigate, right, it declined by a substantial amount, because if we had been up 7% and we normally expanded 6% within the country, then overseas was down.

John Gibson

executive
#56

Joseph, that loss didn’t happen, for the most part—it shifted to later quarters. Yes, there was a slowdown. What you need to take into account regarding the Middle East is this: because of COVID in India, a lot of the field workers going back and forth to the Middle East are Indian, Pakistani, and from other places; as a result, with COVID rising in countries nearby, the capacity to do business there declines, and you’ll see activity levels rise again.

Mike Borton

executive
#57

Plus, the weather played a part. It's the weather...

John Gibson

executive
#58

Right, the weather factored in too. So it — what I mean is — even so, no business was lost on our end. Nothing strikes me as having been missed; instead, things simply shifted a bit later. At this point, they're sitting where the U.S. stood 3 or 6 months back, roughly speaking — I'd call it the Middle East's version of Uri. Q2 is looking robust as of now, provided nothing slides, and we're observing fairly solid momentum here in Q2. So there's no basis to doubt it'll be a meaningful contributor this year — it just contributed less in Q1; and I believe — with the Verax system going international, my sense is we'll witness a sizable uplift.

Joseph Von Meister

analyst
#59

Alright, final question. From what I've been through, going up against the giant can be rough — and in this scenario, ADM would be that giant. So why shouldn't I be — what's the right way for me to weigh that danger when it comes to you folks? They could keep at you forever, so does this ever keep you awake at night?

John Gibson

executive
#60

Joseph, I suppose it hinges on your perspective. To me, I've never come across a more clear-cut case — a contract violation, and in whatever courtroom you bring it to, they broke it. So we ended the agreement, not buying curve paying, there's no need for it, and it benefits the company, no doubt about it. That makes it a favorable result for us. Getting back money we've already laid out would be a bonus for the company, and since there's a dispute, we have to step in and examine that with them in the proper venues in court, so we've reached out to them and we're working it through. But I don't — I consider myself a big guy, and I see us as big guys who get big gas, especially when it rests on the facts, and it rests on what the contract merits rather than on size, and I believe the facts and the contractual merits favor us, and we're going to go in and see whether we can settle this properly.

John Gibson

executive
#61

Honestly, I can’t express enough gratitude to all of you as shareholders, and for the attention you’ve shown this company—and I’d say the patience has paid off. My sense is that we’re on the verge of steady gains; our bench is stronger, our conversations with customers are stronger, and we’re rebuilding those connections into the indirect channel and with the oilfield service companies. So it really feels as though many factors are working in our favor. For Q2, we’ll still see—we will get better from one quarter to the next, though by how much remains an open question for me, while this year’s second half appears very robust when it comes to the market and the way we’re communicating our story. And even more crucially, regardless of whether you assume things stay level as we move into 2022, there’s substantial room for us to capture share from those lacking a green narrative, those without an ESG offering—so a huge lift isn’t necessary for us to exceed our targets, and we’ll stay focused on the work of creating value for all of you; that’s where our attention is. Many thanks, and we can’t wait to speak with you again in the next quarter.

Operator

operator
#62

This concludes our conference. Thank you for attending today's presentation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Flotek Industries, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Flotek Industries, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Flotek Industries, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.